GHO Capital Partners LLP

Season's greetings from all of us at GHO Capital! We wish you a wonderful holiday season and all the best in the year to come!

To strengthen our mission in delivering Better, Faster, More Accessible healthcare, we are proud to announce that we have established a Purpose Advisory Council comprised of external impartial specialists: https://lnkd.in/dHPE4JgF   Chaired by Operating Partner, Alistair Macdonald, the advisory council will also support GHO in remaining aligned with our responsible investment principles, policies and actions.   #BetterFasterMoreAccessible #GHOCapital #ResponsibleInvesting #AdvisoryCouncil

We are proud to announce that we have entered into a definitive merger agreement to acquire Avid Bioservices, a dedicated biologics contract development and manufacturing organization working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, with Ampersand Capital Partners. Read the release: https://lnkd.in/dSEXrWA6 #Acquisition #CDMO #BetterFasterMoreAccessible

GHO Capital’s growth playbook is differentiated by our extensive network comprised of the best minds in transatlantic healthcare investment, spanning industry executives, senior advisers and technical experts. Access to this deep knowledge and experience across all specific subsectors in the healthcare industry is a key source for the investment team and helps guide our portfolio leadership.   Our Operating Partner, james datin, has authored an opinion piece in which he discusses his experience as former CEO and President of BioAgilytix, and how his personal network has provided value for GHO Capital portfolio companies.   To read more: https://lnkd.in/dPF_XBzT   #healthcare #medicaldevices 

Great to see David W. Miller, the CEO of our portfolio company Genesis Research Group, featured in Life Science Leader, explaining how real-world evidence solutions, health economics, and market access solutions are enabling pharmaceutical companies to navigate the regulatory and financial challenges of the current life sciences market.

Fantastic to see our portfolio company Ardena expanding its drug product services in the US with the acquisition of a Center of Excellence for Hot Melt Extrusion (HME) and Fluid Bed technologies in New Jersey. This newly established transatlantic footprint for the business, enhances the Company’s capabilities in downstream late-stage and small-scale commercial manufacturing of oral drugs, supporting its strategy to become a leading global CDMO offering integrated solutions across the full pharma development lifecycle. You can read the news in full here: https://lnkd.in/e7ZzpXQs #CDMO #Acquisition #Healthcare

We would like to congratulate our portfolio company Sanner Group on its acquisition of Gilero, a world-leading medical device and drug delivery system CDMO.   This move will enhance Sanner Group’s offering, positioning the business as a leading provider of end-to-end services across drug delivery, diagnostics and medtech device sectors. With facilities across the United States, Mexico and Ireland, Gilero’s addition is the perfect fit for Sanner and greatly expands its manufacturing and end-to-end capabilities.   To read more: https://lnkd.in/dWAvAjVD     #acqusition #portfoliocompany #healthcare #medicaldevices

Exciting progress in the roll-out of sickle cell disease treatment coming from the US as a 12-year-old becomes one of the first patients to receive FDA approved gene therapy following approvals last year. At GHO Capital, we are proud of the work that our portfolio company RoslinCT is doing to contribute to this progress through its manufacture of Vertex Pharmaceuticals’ CASGEVY™. Through these innovations, we look forward to a future when genetic disorders can be effectively treated with a suite of advanced gene therapies. Read the full article here: https://lnkd.in/de52CEpC #GeneTherapy #SickleCellDisease #RoslinCT #HealthcareInvestment

We are delighted to welcome Martin Dewhurst to GHO Capital as a Senior Advisor. With over 30 years of global experience across the life science industry, most notably co-leading McKinsey & Company Global Life Sciences Practice and co-founding its Health Institute, we look forward to working closely with Martin across investment opportunities and strategic initiatives to continue delivering Better, Faster and More Accessible Healthcare. #NewJoiner #Healthcare

UK patients are set to be the first in the world to be treated with Casgevy, the world’s first approved CRISPR gene-editing therapy for beta thalassemia, following approval from the NICE - National Institute for Health and Care Excellence   We are proud that our portfolio company RoslinCT manufactures this therapy in partnership with Vertex Pharmaceuticals. #genetherapy #casgevy